Orelabrutinib
Orelabrutinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase BTK.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | 14 | 1 | 1 | 1 | 17 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | 28 | 7 | — | 1 | 36 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 9 | 3 | — | 4 | 16 |
| B-cell lymphoma | D016393 | — | — | 1 | 8 | 2 | — | 2 | 12 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 5 | 4 | — | — | 9 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | 1 | — | 1 | 4 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 1 | 3 | 1 | — | — | 4 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | 3 | 1 | — | — | 4 |
| Lymphoid leukemia | D007945 | — | C91 | — | 1 | 1 | — | 1 | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | 1 | — | — | 3 |
| Leukemia | D007938 | — | C95 | — | 1 | 1 | — | — | 2 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | 4 | — | — | — | 4 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 2 | 2 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | 1 | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | — | — | — | 1 |
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | — | 1 | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | — | 1 | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | — | — | 1 | 1 |
| Neoplasms by histologic type | D009370 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Orelabrutinib |
| INN | orelabrutinib |
| Description | Orelabrutinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase BTK. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1655504-04-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4650321 |
| ChEBI ID | — |
| PubChem CID | 91667513 |
| DrugBank | DB16272 |
| UNII ID | WJA5UO9E10 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
BTK
BTK
Organism
Homo sapiens
Gene name
BTK
Gene synonyms
AGMX1, ATK, BPK
NCBI Gene ID
Protein name
tyrosine-protein kinase BTK
Protein synonyms
agammaglobulinaemia tyrosine kinase, Agammaglobulinemia tyrosine kinase, ATK, B-cell progenitor kinase, BPK, Bruton agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, Bruton's tyrosine kinase, dominant-negative kinase-deficient Brutons tyrosine kinase
Uniprot ID
Mouse ortholog
Btk (12229)
tyrosine-protein kinase BTK (Q61365)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 330 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
120 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use